CA-TELESIGN
22.10.2019 22:33:38 CEST | Business Wire | Press release
TeleSign , a leader in authentication and communication services, a wholly-owned subsidiary of BICS, today announced a new partnership with Proximus , the largest telecommunications company in Belgium. This partnership will provide TeleSign’s fraud risk product portfolio to provide regional and international companies with a presence in Belgium.
As the mobile identity ecosystem continues to rapidly evolve globally, it is more important than ever that businesses ensure the strongest authentication and verification measures to secure end-user accounts and prevent fraud, especially in the financial sector. According to PwC , almost two-thirds (65 percent) of companies in Belgium experienced economic crime in the last two years, compared to under half (49 percent) globally. Fraud such as account take over (ATO) through SIM swap and porting attacks can be significantly expensive to both end users and businesses. With the strength of Proximus’ insights and TeleSign’s expertise, this partnership will aid businesses in complying with the new EU Payment Services Directive, PSD2 and its two core use cases – Know Your Customer (KYC) and Strong Customer Authentication (SCA) .
This new partnership with Proximus highlights the increasing importance of Mobile Identity and the key role played by Mobile Operators in digital transformation. It represents a new opportunity to Mobile Operators worldwide to participate in a Global Mobile Identity ecosystem and improve the security of their end users online.
“TeleSign helps its customers globally to protect and prevent fraudulent activity for the end user and businesses,” said Pierre Demarche, VP of Products at TeleSign. “Telesign has existing partnerships with other Mobile Operators in multiple geographies, and keeps expanding its partnership with Mobile Operators worldwide, so we have a deep understanding of how Mobile Identity can be leveraged to provide end-to-end security experience. This protection not only works to prevent costly fraud, but also enhances the user experience.”
“As the leading telecommunications company in Belgium, quality of data and security services to our customers is top of mind, and so is being able to develop services that will protect our customers from fraudulent activity,” said Jeroen Degadt, Director Carrier and Wholesale at Proximus. “Partnering with TeleSign, a global neutral aggregator, was the clear choice. With access to TeleSign’s fraud risk product portfolio, we will be able to provide increased security and assurance for our customers across the country.”
TeleSign is a trusted partner to 21 of the top 25 global websites and mobile applications, enabling them to securely and effectively communicate with billions of end-user accounts. TeleSign offers telecommunications companies like Proximus the ability to secure their customer base and protect users from fraud and identity theft.
For more information about how TeleSign can support mobile operators, please visit https://info.telesign.com/Suppliers.html .
About TeleSign
TeleSign connects and protects online experiences with sophisticated customer identity and engagement solutions. Through APIs that deliver user verification, data insights, and communications we solve today’s unique customer challenges by bridging your business to the complex world of global telecommunications. TeleSign is a subsidiary of BICS, Brussels. BICS is a leading international communications enabler, one of the key global voice carriers and the leading provider of mobile data services worldwide with Proximus as its majority shareholder.
Learn more at www.telesign.com and follow us on Twitter at @TeleSign .
About Proximus
The Proximus Group is a telecommunication and ICT company operating in the Belgian and international markets, serving residential customers, businesses, and public institutions. Proximus aims to open up a world of digital opportunities so that people can live better and work smarter. The company is at the heart of the digital revolution, delivering communication and entertainment experiences for residential consumers and enabling digital transformation for enterprises. Through its best-quality integrated fixed and mobile networks, Proximus provides access anywhere and anytime to digital services and easy-to-use solutions, and is a gateway to multimedia content. Proximus is a pioneer in ICT innovation, with integrated solutions that have a positive impact on society and the environment, based on Internet of Things (IoT), Data analytics, cloudification, and security. With 13,385 employees, all striving to offer customers a superior experience, the Group realized an underlying Group revenue of EUR 5,804 million end-2018.
Proximus (Euronext Brussels: PROX) is also active in Luxembourg through its affiliate Proximus Luxembourg and in the Netherlands through Telindus Netherlands. BICS is a leading international communications enabler, one of the key global voice carriers, and the leading provider of mobile data services worldwide.
For more information, visit www.proximus.com and www.proximus.be .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191022005356/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom